Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?

Key Takeaways Novo Nordisk cut 2025 guidance as Wegovy and Ozempic face slower uptake and Eli Lilly rivalry.VKTX's VK2735 showed strong weight loss but raised safety and tolerability concerns in an ongoing study.Despite no marketed product, VKTX's valuation and cash position make it a safer relative bet.Novo Nordisk (NVO) and Viking Therapeutics (VKTX) have emerged as notable players in the obesity space.A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names Ozempic ...